BrainStorm

About

Funding history · 16 rounds · $197.2M total

Headcount over time

Offices

Q&A

What is BrainStorm Cell Therapeutics' primary focus?

BrainStorm Cell Therapeutics is a biotechnology company focused on developing autologous adult stem cell therapies for debilitating neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), and Alzheimer's disease (AD).

What is BrainStorm Cell Therapeutics' proprietary technology platform?

BrainStorm's proprietary NurOwn® platform uses a patient's own mesenchymal stem cells (MSCs) to generate neurotrophic factor-secreting cells (MSC-NTF cells) designed to modulate neuroinflammation and promote neuroprotection.

When did BrainStorm Cell Therapeutics become a public company?

BrainStorm Cell Therapeutics went public on NASDAQ in October 2003.

What was the most recent funding round for BrainStorm Cell Therapeutics?

The most recent funding round for BrainStorm Cell Therapeutics was a PIPE round in February 2026, raising $1,000,000.

What was the amount raised in BrainStorm Cell Therapeutics' Public Offering in June 2024?

In June 2024, BrainStorm Cell Therapeutics completed a Public Offering that raised $4,000,000.

What is the current employee count for BrainStorm Cell Therapeutics?

BrainStorm Cell Therapeutics has an employee count in the 11-50 range.

What is the status of BrainStorm's NurOwn® Phase 3b trial for ALS?

In May 2025, BrainStorm received FDA clearance to initiate the Phase 3b trial of NurOwn® for ALS.

What recent strategic partnership did BrainStorm Cell Therapeutics secure for NurOwn® manufacturing?

In May 2025, BrainStorm secured a manufacturing partnership with Minaris for the upcoming NurOwn® Phase 3b ALS clinical trials.

What is the status of BrainStorm Cell Therapeutics' listing on stock exchanges?

In July 2025, BrainStorm Cell Therapeutics announced its delisting from Nasdaq and transition to the OTCQB Venture Market, where its ticker is BCLI.

What was a significant finding from BrainStorm's Expanded Access Program for ALS patients?

In June 2025, BrainStorm announced new survival data from its Expanded Access Program cohort, showing that 90% of ALS patients survived over 5 years with NurOwn®.

Team · 20

Irit Arbel

Founder · Board of Directors

Daniel Offen

Founder · Chief Scientist

Chaim Lebovits

President, Chief Executive Officer

Haro Hartounian

Executive Vice President, Chief Operating Officer

Uri Yablonka

Executive Vice President, Chief Business Officer

Bob Dagher

Executive Vice President, Chief Medical Officer

Mary Kay Turner

Senior Vice President, Patient Advocacy and Government Affairs

Netta Blondheim-Shraga

Senior Vice President, Research and Development

Yossef Levy

Vice President, Cell Production

Leticia Tarilonte

Vice President, Global Clinical Operations

Alla Patlis

Interim Chief Financial Officer

Menghis Bairu

Board of Directors

Jacob Frenkel

Board of Directors

Stacy Lindborg

Board of Directors

Nir Naor

Board of Directors

LinkedIn ↗

Anthony Polverino

Board of Directors

Jerold Chun

Scientific Advisory Board

Stanley H. Appel

Scientific Advisory Board

Amit Bar-Or

Scientific Advisory Board

Ralph Kern

Scientific Advisory Board

Sectors & technology

Highlights

Tags